ALK Fusions in a Wide Variety of Tumor Types Respond to Anti‐ALK Targeted Therapy

BACKGROUND. Genomic fusions of the anaplastic lymphoma kinase gene (ALK) are a well‐established therapy target in non‐small cell lung cancer (NSCLC). From a survey of 114,200 clinical cases, we determined the prevalence of ALK rearrangements (rALK) in non‐NSCLC tumors and report their responsiveness...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Ross, Jeffrey S., Ali, Siraj M., Fasan, Omotayo, Block, Jared, Pal, Sumanta, Elvin, Julia A., Schrock, Alexa B., Suh, James, Nozad, Sahar, Kim, Sungeun, Jeong Lee, Hwa, Sheehan, Christine E., Jones, David M., Vergilio, Jo‐Anne, Ramkissoon, Shakti, Severson, Eric, Daniel, Sugganth, Fabrizio, David, Frampton, Garrett, Miller, Vince A., Stephens, Philip J., Gay, Laurie M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2017
Konular:
Cancer Diagnostics and Molecular Pathology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728036/
https://ncbi.nlm.nih.gov/pubmed/29079636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0488
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller